JAB 22000
Alternative Names: JAB-22000Latest Information Update: 09 Dec 2021
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 01 Dec 2021 JAB 22000 is available for licensing as of 01 Dec 2021. http://en.jacobiopharma.com/intro/19.html
- 25 Oct 2021 Early research in Adenocarcinoma in China (unspecified route) (Jacobio Pharmaceuticals pipeline, October 2021)
- 25 Oct 2021 Early research in Colorectal cancer in China (unspecified route) (Jacobio Pharmaceuticals pipeline, October 2021)